Fibrinogen interaction with human platelets: Effect of other coagulation factors, prostaglandins and platelet inhibitors

Hamid Al-Mondhiry, James Ballard, Virginia McGarvey

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Fibrinogen (fg) binding to platelets is a critical step in the formation of the hemostatic plug. The interaction requires platelet stimulation and the induction of receptor sites on the platelet membrane. In this paper we report on the effect of other clotting factors on 125I-labeled fg binding to gel filtered human platelets. The action of exogenously added or endogenously synthesized prostaglandins and the effect of antiplatelet drugs were also investigated. Prothrombin and active factor X enhance ADP-induced platelet-fg binding whereas active factor VIII and active factor IX, separately or combined, are without effect. Human prothrombin complex (PC) factor concentrates (II-VII-IX-X) cause significant enhancement of platelets-fg binding; this effect is most likely due to activated factors and/or traces of thrombin present in the preparation. In the concentration used, these clotting factors and the PC factor concentrates failed to aggregate platelets in platelet rich plasma. Acetylsalicylic acid, carbenicillin and the calcium channel blocking agents verapamil and nifedipine showed variable degrees of inhibition of ADP-induced platelet-fg binding. Chlorpromazine and propranolol were without effect. Estrogen and progesterone had some enhancing effect on binding. These results suggest that, when the hemostatic mechanism is initiated, thromboxane A2 synthesis and activated prothrombin complex factors significantly enhance fg binding to platelets, a key step in hemostasis. Inhibitors of aggregation do not necessarily impede platelet fibrinogen interaction.

Original languageEnglish (US)
Pages (from-to)415-426
Number of pages12
JournalThrombosis Research
Volume31
Issue number3
DOIs
StatePublished - Aug 1 1983

Fingerprint

Prostaglandin Antagonists
Blood Coagulation Factors
Platelet Aggregation Inhibitors
Fibrinogen
Blood Platelets
Prothrombin
Hemostatics
Adenosine Diphosphate
Carbenicillin
Factor X
Thromboxane A2
Factor IX
Platelet-Rich Plasma
Chlorpromazine
Factor VIII
Calcium Channels
Nifedipine
Verapamil
Hemostasis
Propranolol

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

@article{e364f09a01ed460097d3a5b1d8a9f79b,
title = "Fibrinogen interaction with human platelets: Effect of other coagulation factors, prostaglandins and platelet inhibitors",
abstract = "Fibrinogen (fg) binding to platelets is a critical step in the formation of the hemostatic plug. The interaction requires platelet stimulation and the induction of receptor sites on the platelet membrane. In this paper we report on the effect of other clotting factors on 125I-labeled fg binding to gel filtered human platelets. The action of exogenously added or endogenously synthesized prostaglandins and the effect of antiplatelet drugs were also investigated. Prothrombin and active factor X enhance ADP-induced platelet-fg binding whereas active factor VIII and active factor IX, separately or combined, are without effect. Human prothrombin complex (PC) factor concentrates (II-VII-IX-X) cause significant enhancement of platelets-fg binding; this effect is most likely due to activated factors and/or traces of thrombin present in the preparation. In the concentration used, these clotting factors and the PC factor concentrates failed to aggregate platelets in platelet rich plasma. Acetylsalicylic acid, carbenicillin and the calcium channel blocking agents verapamil and nifedipine showed variable degrees of inhibition of ADP-induced platelet-fg binding. Chlorpromazine and propranolol were without effect. Estrogen and progesterone had some enhancing effect on binding. These results suggest that, when the hemostatic mechanism is initiated, thromboxane A2 synthesis and activated prothrombin complex factors significantly enhance fg binding to platelets, a key step in hemostasis. Inhibitors of aggregation do not necessarily impede platelet fibrinogen interaction.",
author = "Hamid Al-Mondhiry and James Ballard and Virginia McGarvey",
year = "1983",
month = "8",
day = "1",
doi = "10.1016/0049-3848(83)90406-1",
language = "English (US)",
volume = "31",
pages = "415--426",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "3",

}

Fibrinogen interaction with human platelets : Effect of other coagulation factors, prostaglandins and platelet inhibitors. / Al-Mondhiry, Hamid; Ballard, James; McGarvey, Virginia.

In: Thrombosis Research, Vol. 31, No. 3, 01.08.1983, p. 415-426.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fibrinogen interaction with human platelets

T2 - Effect of other coagulation factors, prostaglandins and platelet inhibitors

AU - Al-Mondhiry, Hamid

AU - Ballard, James

AU - McGarvey, Virginia

PY - 1983/8/1

Y1 - 1983/8/1

N2 - Fibrinogen (fg) binding to platelets is a critical step in the formation of the hemostatic plug. The interaction requires platelet stimulation and the induction of receptor sites on the platelet membrane. In this paper we report on the effect of other clotting factors on 125I-labeled fg binding to gel filtered human platelets. The action of exogenously added or endogenously synthesized prostaglandins and the effect of antiplatelet drugs were also investigated. Prothrombin and active factor X enhance ADP-induced platelet-fg binding whereas active factor VIII and active factor IX, separately or combined, are without effect. Human prothrombin complex (PC) factor concentrates (II-VII-IX-X) cause significant enhancement of platelets-fg binding; this effect is most likely due to activated factors and/or traces of thrombin present in the preparation. In the concentration used, these clotting factors and the PC factor concentrates failed to aggregate platelets in platelet rich plasma. Acetylsalicylic acid, carbenicillin and the calcium channel blocking agents verapamil and nifedipine showed variable degrees of inhibition of ADP-induced platelet-fg binding. Chlorpromazine and propranolol were without effect. Estrogen and progesterone had some enhancing effect on binding. These results suggest that, when the hemostatic mechanism is initiated, thromboxane A2 synthesis and activated prothrombin complex factors significantly enhance fg binding to platelets, a key step in hemostasis. Inhibitors of aggregation do not necessarily impede platelet fibrinogen interaction.

AB - Fibrinogen (fg) binding to platelets is a critical step in the formation of the hemostatic plug. The interaction requires platelet stimulation and the induction of receptor sites on the platelet membrane. In this paper we report on the effect of other clotting factors on 125I-labeled fg binding to gel filtered human platelets. The action of exogenously added or endogenously synthesized prostaglandins and the effect of antiplatelet drugs were also investigated. Prothrombin and active factor X enhance ADP-induced platelet-fg binding whereas active factor VIII and active factor IX, separately or combined, are without effect. Human prothrombin complex (PC) factor concentrates (II-VII-IX-X) cause significant enhancement of platelets-fg binding; this effect is most likely due to activated factors and/or traces of thrombin present in the preparation. In the concentration used, these clotting factors and the PC factor concentrates failed to aggregate platelets in platelet rich plasma. Acetylsalicylic acid, carbenicillin and the calcium channel blocking agents verapamil and nifedipine showed variable degrees of inhibition of ADP-induced platelet-fg binding. Chlorpromazine and propranolol were without effect. Estrogen and progesterone had some enhancing effect on binding. These results suggest that, when the hemostatic mechanism is initiated, thromboxane A2 synthesis and activated prothrombin complex factors significantly enhance fg binding to platelets, a key step in hemostasis. Inhibitors of aggregation do not necessarily impede platelet fibrinogen interaction.

UR - http://www.scopus.com/inward/record.url?scp=0021041391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021041391&partnerID=8YFLogxK

U2 - 10.1016/0049-3848(83)90406-1

DO - 10.1016/0049-3848(83)90406-1

M3 - Article

C2 - 20217998

AN - SCOPUS:0021041391

VL - 31

SP - 415

EP - 426

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 3

ER -